UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (785) 785
Patent (175) 175
Conference Proceeding (41) 41
Newspaper Article (18) 18
Book Chapter (15) 15
Magazine Article (2) 2
Technical Report (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (409) 409
life sciences & biomedicine (348) 348
humans (284) 284
oncology (268) 268
female (155) 155
male (152) 152
aged (126) 126
lung neoplasms - drug therapy (124) 124
middle aged (119) 119
electricity (110) 110
basic electric elements (106) 106
carcinoma, non-small-cell lung - drug therapy (106) 106
electric solid state devices not otherwise provided for (106) 106
semiconductor devices (106) 106
lung cancer (99) 99
lung neoplasms - pathology (95) 95
cancer (81) 81
adult (78) 78
carcinoma, non-small-cell lung - pathology (73) 73
mutation (66) 66
abridged index medicus (60) 60
aged, 80 and over (60) 60
care and treatment (60) 60
antineoplastic combined chemotherapy protocols - therapeutic use (58) 58
treatment outcome (58) 58
respiratory system (55) 55
neoplasm staging (52) 52
lung neoplasms - genetics (51) 51
lung neoplasms - mortality (51) 51
analysis (47) 47
carcinoma, non-small-cell lung - genetics (41) 41
chemotherapy (41) 41
research (40) 40
antineoplastic agents - therapeutic use (39) 39
chemistry (38) 38
animals (36) 36
lung cancer, non-small cell (35) 35
carcinoma, non-small-cell lung - mortality (34) 34
prognosis (33) 33
technology (33) 33
health aspects (32) 32
patients (31) 31
physics (31) 31
survival rate (31) 31
disease-free survival (30) 30
lung neoplasms - therapy (30) 30
hematology, oncology and palliative medicine (29) 29
physical sciences (29) 29
tumors (29) 29
electric techniques not otherwise provided for (28) 28
apoptosis (27) 27
biochemistry & molecular biology (26) 26
casings or constructional details of electric apparatus (26) 26
manufacture of assemblages of electrical components (26) 26
nsclc (26) 26
printed circuits (26) 26
pulmonary and respiratory medicine (26) 26
survival analysis (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
cell line, tumor (25) 25
non-small cell lung cancer (25) 25
cell biology (24) 24
clinical trials (24) 24
protein kinase inhibitors - therapeutic use (24) 24
cancer therapies (23) 23
neoplasms - drug therapy (23) 23
patient outcomes (23) 23
pharmacology & pharmacy (23) 23
carboplatin - administration & dosage (22) 22
immunotherapy (21) 21
neoplasms - pathology (21) 21
non-small cell lung carcinoma (21) 21
paclitaxel - administration & dosage (21) 21
survival (21) 21
erbb receptors - genetics (20) 20
lung neoplasms - metabolism (20) 20
diagnosis (19) 19
epidermal growth factor receptor (19) 19
erlotinib (19) 19
mice (19) 19
risk factors (19) 19
antineoplastic agents - pharmacology (18) 18
carcinoma, non-small-cell lung - therapy (18) 18
proteins (18) 18
pulmonary/respiratory (18) 18
science & technology - other topics (18) 18
united states (18) 18
usage (18) 18
young adult (18) 18
clinical trials as topic (17) 17
egfr (17) 17
epidermal growth factor (17) 17
erbb receptors - antagonists & inhibitors (17) 17
general & internal medicine (17) 17
kaplan-meier estimate (17) 17
metallurgy (17) 17
retrospective studies (17) 17
surgery (17) 17
adenocarcinoma (16) 16
antibodies, monoclonal - administration & dosage (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


SAE technical paper series, Volume 2012-01-0779.
In this ever-changing field of automotive industry where there is high competition to seek a place in market, it is necessary to design and develop products... 
Pumps | Engine components | Mathematical models
eJournal
The lancet oncology, ISSN 1470-2045, 03/2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
PloS one, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, pp. e81162 - e81162
Cisplatin is one of the most effective and widely used anticancer agents for the treatment of several types of tumors. The cytotoxic effect of cisplatin is... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | DNA Repair - drug effects | Reactive Oxygen Species - metabolism | Oxidation-Reduction | Apoptosis - drug effects | Saccharomyces cerevisiae - genetics | Humans | DNA Adducts - chemistry | Saccharomyces cerevisiae - drug effects | Mitochondria - metabolism | Cisplatin - pharmacology | DNA - metabolism | Mitochondria - drug effects | Reactive Oxygen Species - agonists | Saccharomyces cerevisiae - metabolism | DNA - chemistry | Animals | Cell Nucleus - metabolism | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | DNA Damage | Cell Nucleus - drug effects | Care and treatment | DNA replication | Cell death | Oncology, Experimental | Protein biosynthesis | Mitochondrial DNA | Research | Genetic transcription | Cisplatin | Cancer | Oxidative stress | Phosphorylation | Baking yeast | Transcription | Toxicity | Pathogenesis | DNA damage | Cytotoxicity | Oncology | Biochemistry | Drug development | Kinases | Tissues | Blockage | Anticancer properties | Signal transduction | Mitochondria | Antitumor agents | Biocompatibility | Stress response | Damage | Drug dosages | Deoxyribonucleic acid--DNA | Adducts | Killing | Medical research | Hematology | Exposure | Tumor cell lines | Studies | DNA biosynthesis | Survival analysis | Protein synthesis | Medical prognosis | DNA adducts | Tumors | Apoptosis | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Oncology times, ISSN 0276-2234, 07/2011, Volume 33, Issue 14, pp. 12 - 13
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 05/2017, Volume 114, Issue 19, pp. 4993 - 4998
Exhausted T cells in chronic infections and cancer have sustained expression of the inhibitory receptor programmed cell death 1 (PD-1). Therapies that block... 
Checkpoint inhibition | T-cell exhaustion | Cancer immunotherapy | PD-1 | CD8 T cells | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | CD8-Positive T-Lymphocytes - pathology | Humans | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Lymphocyte Activation - drug effects | Female | Cell Proliferation - drug effects | Carcinoma, Non-Small-Cell Lung - drug therapy | CD8-Positive T-Lymphocytes - immunology | Flow cytometry | Care and treatment | Usage | Lung cancer | Immunotherapy | Research | T cells | CD27 antigen | Cell proliferation | Therapy | Bcl-2 protein | PD-1 protein | CD8 antigen | Effector cells | Lymphocytes T | CD28 antigen | Blood | Molecules | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | CD38 antigen | Peripheral blood | Non-small cell lung carcinoma | T cell receptors | Patients | Cell death | Bcl protein | Biomarkers | Histocompatibility antigen HLA | Apoptosis | Tumors | Cancer | Index Medicus | Biological Sciences | checkpoint inhibition | cancer immunotherapy
Journal Article